A practical reference on phase 2 trial: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-13. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Beginning in 1939, Drew traveled every year to Tuskegee, Alabama, to attend the annual free clinic at the John A. Andrew Memorial Hospital. For the 1950 Tuskegee clinic, Drew drove along with three other black physicians. Drew was driving around 8 a.m. on April 1. Still fatigued from spending the night before in the operating theater, he lost control of the vehicle. After careening into a field, the car somersaulted three times. The three other physicians sustained minor injuries. Drew was trapped with severe wounds; his foot was wedged beneath the brake pedal. When reached by emergency technicians, he was in shock and barely alive due to severe leg injuries. Drew was taken to Alamance General Hospital in Burlington, North Carolina. He was pronounced dead a half hour after he first received medical attention. Drew's funeral was held on April 5, 1950, at the Nineteenth Street Baptist Church in Washington, D.C. Despite a popular myth to the contrary, once repeated on an episode ("Dear Dad... Three") of the TV series M*A*S*H and in the novels Carrion Comfort, The 480, and The Human Stain, Drew's death was not the result of his having been refused hospital access because of his race. According to John Ford, one of the passengers in Drew's car, Drew's injuries were so severe that virtually nothing could have been done to save him. Ford added that a blood transfusion might have actually killed Drew sooner.
1⁄2 H2 → H+ + e− The electrode potential of each half-reaction is also known as its reduction potential (Eored), or potential when the half-reaction takes place at a cathode. The reduction potential is a measure of the tendency of the oxidizing agent to be reduced. Its value is zero for H+ + e− → 1⁄2H2 by definition, positive for oxidizing agents stronger than H+ (e.g., +2.866 V for F2) and negative for oxidizing agents that are weaker than H+ (e.g., −0.763V for Zn2+). For a redox reaction that takes place in a cell, the potential difference is:
=== Schizophrenia === Schizophrenia is a chronic mental health condition caused by changes in brain chemistry and structure. Genetics and environment are hypothesized to play a key role in development of this disorder. Research suggests impaired gene expression or chemical imbalance may impact this condition. Anxiety can increase risk of schizophrenia and symptoms include hallucinations, disorganized speech, and abnormal behavior. Davunetide (NAP) is a segment of activity-dependent neuroprotective protein (ADNP). ADNP is reported be downregulated with schizophrenia. A study observed decreased hyperactivity in mice when treated with NAP via the intranasal route.
== Signs and symptoms == The characteristics of a burn depend upon its depth. Superficial burns cause pain lasting two or three days, followed by peeling of the skin over the next few days. Individuals with more severe burns may indicate discomfort or complain of feeling pressure rather than pain. Full-thickness burns may be entirely insensitive to light touch or puncture. While superficial burns are typically red in color, severe burns may be pink, white or black. Burns around the mouth or singed hair inside the nose may indicate that burns to the airways have occurred, but these findings are not definitive. More worrisome signs include: shortness of breath, hoarseness, and stridor or wheezing. Itchiness is common during the healing process, occurring in up to 90% of adults and nearly all children. Numbness or tingling may persist for a prolonged period of time after an electrical injury. Burns may also produce emotional and psychological distress.
=== Natural toxins === Several foods can naturally contain toxins, many of which are not produced by bacteria. Plants in particular may be toxic; animals which are naturally poisonous to eat are rare. In evolutionary terms, animals can escape being eaten by fleeing; plants can use only passive defenses such as poisons and distasteful substances, for example capsaicin in chili peppers and pungent sulfur compounds in garlic and onions. Most animal poisons are not synthesised by the animal, but acquired by eating poisonous plants to which the animal is immune, or by bacterial action.
Sources: en.wikipedia.org
As field rations are intended to last long, the packaging they are stored in is designed to ensure a long shelf life and prevent spoilage, while also being light and compact enough to be carried without issue. Rations are canned, vacuum-sealed, or freeze-dried foods stored in packages to prevent leakage or spoilage, commonly retort pouches, boxes, or cases. These containers are preferably easy to open anywhere, though some may require specific tools that are issued to soldiers or included in the ration package, such as the American P-38 can opener or Australian field ration eating device. Some, but not all, ration packages may be biodegradable or compostable.
== Peptides-to-Drugs (P2D) platform == Based on its P2D platform, Jerini established several in-house development programs, to address indications within the ophthalmology, oncology, and inflammatory therapeutic areas. The most advanced of these programs targeted age-related macular degeneration (AMD), the leading cause of vision loss and blindness in people over the age of 55 in developed countries. Jerini's compound (JSM 6427) has shown significant efficacy in combating disease progression in preclinical models. Jerini's proprietary Peptides-to-Drugs (P2D) technology was used to identify peptide drug lead structures and systematically transform them into peptidomimetic (injectable) and small-molecule (oral) drugs, depending on the indication. This enabled Jerini to develop novel drug candidates for diseases that were difficult to access using traditional drug discovery methods. The ability to produce both peptidomimetics and small molecule drugs as drug candidates has enabled the simultaneous development of drugs for acute and chronic treatments against the same target molecule (target).
While it is a common belief that breastfeeding causes breasts to sag, researchers have found that a woman's breasts sag due to four key factors: cigarette smoking, number of pregnancies, gravity, and weight loss or gain. Women sometimes wear bras because they mistakenly believe they prevent breasts from sagging as they get older. Physicians, lingerie retailers, teenagers, and adult women used to believe that bras were medically required to support breasts. In a 1952 article in Parents' Magazine, Frank H. Crowell erroneously reported that it was important for teen girls to begin wearing bras early. According to Crowell, this would prevent sagging breasts, stretched blood vessels, and poor circulation later on. This belief was based on the false idea that breasts cannot anatomically support themselves. Sports bras are sometimes used for cardiovascular exercise, sports bras are designed to secure the breasts closely to the body to prevent movement during high-motion activity such as running. Studies have indicated sports bras which are overly tight may restrict respiratory function.
According to the United Nations Office on Drugs and Crime World Drug Report, approximately 21 million people worldwide use ecstasy-type substances, including MDMA. This accounts for roughly 0.4% of the global population aged 15 to 64. In the United States, according to the Substance Abuse and Mental Health Services Administration 2021 National Survey on Drug Use and Health, among people aged 12 or older, 0.8% (2.2 million people) reported the use of ecstasy in the past year. Usage is much higher among attendees of nightclubs and dance festivals and among people aged in their late 20s.
Sources: en.wikipedia.org
== Further reading == Webster, Gregory K.; Kott, L; Maloney, T; et al. (2005). "JALA Tutorial: Considerations When Implementing Automated Methods into GxP Laboratories". Journal of the Association for Laboratory Automation. 10 (3). Elsevier: 182–191. doi:10.1016/j.jala.2005.03.003.
Sir Joseph John Thomson (18 December 1856 – 30 August 1940) was a British physicist. He received the 1906 Nobel Prize in Physics "in recognition of the great merits of his theoretical and experimental investigations on the conduction of electricity by gases." In 1897, he showed that cathode rays were composed of previously unknown negatively charged particles (now called electrons), which he calculated must have bodies much smaller than atoms and a very large charge-to-mass ratio. The electron was the first subatomic particle to be discovered. Thomson is credited with finding the first evidence for isotopes of a stable (non-radioactive) element in 1912, as part of his exploration into the composition of canal rays (positive ions). His experiments to determine the nature of positively charged particles, with Francis William Aston, were the first use of mass spectrometry and led to the development of the mass spectrograph. Thomson was an influential teacher, and seven of his students went on to win Nobel Prizes: Ernest Rutherford (Chemistry 1908), Lawrence Bragg (Physics 1915), Charles Barkla (Physics 1917), Francis Aston (Chemistry 1922), Charles Thomson Rees Wilson (Physics 1927), Owen Richardson (Physics 1928) and Edward Appleton (Physics 1947). His son, George Paget Thomson, shared the 1937 Nobel Prize in Physics with Clinton Davisson "for their experimental discovery of the diffraction of electrons by crystals".
In contrast to short term sample storage at +4 to −20 °C (39 to −4 °F) by using standard refrigerators or freezers, many molecular biology or life science laboratories need long-term cryopreservation (including "cold chain" and/or "colder chain" infrastructures) for biological samples like DNA, RNA, proteins, cell extracts, or reagents. To reduce the risk of sample damage, these types of samples need extremely low temperatures of −80 to −86 °C (−112 to −123 °F). Mammalian cells are often stored in dewars containing liquid nitrogen at −196 °C (−320.8 °F). Cryogenic chest freezers can achieve temperatures down to −150 °C (−238 °F) to −152 °C (−242 °F) and may include a liquid nitrogen backup. Biological samples in ULT freezers are often stored in polymer tubes and microtubes, generally inside storage boxes that are commonly made of cardboard, polymer plastics or other materials. Microtubes are placed in storage boxes containing a grid of dividers that typically permit 64, 81, or 100 tubes to be stored. Standard ULT freezers can store approximately 350 to 450 microtube boxes.
== Branding times == The length of time the brand is applied depends on several factors, such as the thermal conductivity of the metal used, the age of the animal, the thickness of its skin, the color or pigment to its coat, and the amount of hair, if any, that remains between brand and skin after shaving. Although the animal is shaved, the time of brand application also depends on the stage of the animal's hair growth, with rapidly growing spring coats requiring less time and those with winter coats requiring more. It is hypothesized that the pigment-producing melanocytes are more easily destroyed during periods of rapid hair, and hence rapid pigmentation, production. It is important to adhere to brand time guidelines because melanocytes that are merely stressed rather than killed often react by producing even more melanin than they did before their injury. This is the same reaction responsible for skin tanning and the darkening of skin under regular mechanical strain. These failed brands then regrow as dark skin producing even darker hair than was present before, creating a very low-contrast marking.
TAP is a heterodimeric complex, consisting of TAP1 (ABCB2) and TAP2 (ABCB3) members of the ABC transporter superfamily. The common feature of all ABC transporters is their organization: 1) into two transmembrane domains (TMDs) and 2) into two nucleotide-binding domains (NBDs). Both intramolecular domains are coupled to each other and when ATP binding is in progress, conformational changes in the TMDs allow proteasomal degradation products to move across the membrane. TAP recognizes and transports the antigen peptides produced in the cytosol straight into the ER, while tapasin recognizes the kind of peptides that have the ability to form stable complexes with MHC-I. This process is known as peptide proofreading or editing. Peptides selected through proofreading improve MHC-I stability; tapasin also contributes to the editing of immunogenic peptide epitopes. However, only lately it was proven via biochemical, biophysical, and structural studies that a key function in adaptive immunity, the catalytic mechanism of peptide proofreading, is performed by tapasin and TAPBPR (TAP-binding protein-related, a tapasin homologue).
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。